JP Morgan Chase’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

JP Morgan Chase’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	–	–	7578
2023 Q1	$0	Buy	10 +9	+900%	+$34	﹤0.01%	7545
2022 Q4	$0	Sell	1 -1	-50%	-$6	﹤0.01%	7293
2022 Q3	$0	Sell	2 -30	-94%	-$365	﹤0.01%	7094
2022 Q2	$0	Buy	32 +4	+14%	+$38	﹤0.01%	7136
2022 Q1	$0	Buy	28 +26	+1,300%	+$834	﹤0.01%	7231
2021 Q4	$0	Buy	+2	New	+$116	﹤0.01%	7166
2021 Q3	–	Sell	-761	Closed	-$53K	–	6974
2021 Q2	$53K	Buy	761 +758	+25,267%	+$41K	﹤0.01%	5725
2021 Q1	$0	Buy	+3	New	+$228	﹤0.01%	6477

JP Morgan Chase's HTGM Position: Q2 2023 in Review

JP Morgan Chase sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 10 shares.

JP Morgan Chase first reported a position in HTGM in Q1 2021 and held it in 8 quarters. The position peaked at $53K in Q2 2021. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.

JP Morgan Chase reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Chase sold 10 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023.
JP Morgan Chase first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
JP Morgan Chase's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $53K in Q2 2021.
0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.